Neurocrine Biosciences Inc (NBIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurocrine Biosciences Inc (NBIX) has a cash flow conversion efficiency ratio of 0.119x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($388.40 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Neurocrine Biosciences Inc to measure how much of total assets are equity-financed.
Neurocrine Biosciences Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Neurocrine Biosciences Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Neurocrine Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurocrine Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huazhu Group Ltd
NASDAQ:HTHT
|
0.141x |
|
Taiwan Union Technology
TWO:6274
|
-0.087x |
|
CNPC Capital Co Ltd
SHE:000617
|
-0.022x |
|
National Bank of Greece S.A
AT:ETE
|
0.191x |
|
Pro Medicus Ltd
AU:PME
|
0.178x |
|
NESTE OYJ UNSP.ADR 1/2
F:NEFA
|
N/A |
|
GD Power Development Co Ltd
SHG:600795
|
0.121x |
|
Toromont Industries Ltd.
TO:TIH
|
0.038x |
Annual Cash Flow Conversion Efficiency for Neurocrine Biosciences Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Neurocrine Biosciences Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see NBIX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.25 Billion | $782.70 Million | 0.241x | +4.65% |
| 2024-12-31 | $2.59 Billion | $595.40 Million | 0.230x | +31.61% |
| 2023-12-31 | $2.23 Billion | $389.90 Million | 0.175x | -12.10% |
| 2022-12-31 | $1.71 Billion | $339.40 Million | 0.199x | +6.46% |
| 2021-12-31 | $1.37 Billion | $256.50 Million | 0.187x | -7.99% |
| 2020-12-31 | $1.13 Billion | $228.50 Million | 0.203x | -12.09% |
| 2019-12-31 | $636.90 Million | $147.00 Million | 0.231x | +9.43% |
| 2018-12-31 | $480.76 Million | $101.40 Million | 0.211x | +183.21% |
| 2017-12-31 | $372.14 Million | $-94.33 Million | -0.253x | +24.83% |
| 2016-12-31 | $314.88 Million | $-106.18 Million | -0.337x | -276.69% |
| 2015-12-31 | $424.45 Million | $-38.00 Million | -0.090x | +60.37% |
| 2014-12-31 | $208.70 Million | $-47.14 Million | -0.226x | +8.14% |
| 2013-12-31 | $120.41 Million | $-29.61 Million | -0.246x | -7.55% |
| 2012-12-31 | $154.37 Million | $-35.29 Million | -0.229x | -1867.95% |
| 2011-12-31 | $60.08 Million | $-698.00K | -0.012x | -100.45% |
| 2010-12-31 | $19.34 Million | $49.94 Million | 2.582x | +119.23% |
| 2009-12-31 | $3.95 Million | $-53.09 Million | -13.428x | -565.82% |
| 2008-12-31 | $36.77 Million | $-74.17 Million | -2.017x | -303.45% |
| 2007-12-31 | $118.70 Million | $-59.33 Million | -0.500x | -58.37% |
| 2006-12-31 | $314.72 Million | $-99.33 Million | -0.316x | -299.85% |
| 2005-12-31 | $390.10 Million | $-30.79 Million | -0.079x | +68.91% |
| 2004-12-31 | $393.83 Million | $-99.99 Million | -0.254x | -367.46% |
| 2003-12-31 | $391.12 Million | $37.13 Million | 0.095x | +126.82% |
| 2002-12-31 | $224.25 Million | $-79.36 Million | -0.354x | -402.61% |
| 2001-12-31 | $310.39 Million | $-21.86 Million | -0.070x | +38.36% |
| 2000-12-31 | $163.21 Million | $-18.64 Million | -0.114x | -6.92% |
| 1999-12-31 | $96.40 Million | $-10.30 Million | -0.107x | +28.10% |
| 1998-12-31 | $72.00 Million | $-10.70 Million | -0.149x | -212.40% |
| 1997-12-31 | $83.20 Million | $11.00 Million | 0.132x | +43.66% |
| 1996-12-31 | $72.80 Million | $6.70 Million | 0.092x | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more